OLIMINA3® CLINICAL STUDY

MEDICALLY FORMULATED AND CLINICALLY TESTED

The objective of the OLIMINA3® clinical study was to demonstrate that it could reduce CRP levels in women who had overcome breast cancer.. For this, a clinical study of OLIMINA3® has been carried out in 45 patients from the hospitals of La Paz, Ramón y Cajal, Puerta de Hierro and the Quirón group. This research was conducted in collaboration with physicians from Duke University in the United States.

OLIMINA3

OLIMINA3® clinical study,

carried out in 45 breast cancer patients.

La Paz, Ramón y Cajal, Puerta de Hierro, Quirón and Quirón Hospitals

Sanitas La Moraleja.

Researchers have shown that OLIMINA3® can reduce inflammation levels in women who have survived breast cancer.. This is due to the unique patented combination of natural ingredients.
It has also been concluded that it reduces joint pain. Aromatase inhibitors are a common treatment for hormone-sensitive breast cancer patients.. This treatment may cause joint pain.
The experienced scientific team of PHYTOGEN MEDICAL FOODS, with advisers from the United States and Spain, have worked to develop Olimina3.
OLIMINA3® it is a last generation nutritional supplement. Its formula h
The results have shown a decrease in Reactive Protein (CRP) levels in blood and, therefore, an improvement in patients’ well-being.
.

40% PAIN REDUCTION IN BREAST CANCER PATIENTS*.

Pain Olimina3 Assay
Pain parameters and Olimina effect3
Evolution But Pain

– 40% reduction in the Pain Intensity Index, statistically significant.
– Clinically relevant decrease in ALL pain parameters and pain intensity index.
– The reduction amounts to 4 points.

STATISTICALLY SIGNIFICANT DECREASE IN PCR

AND MAINTAINED OVER TIME

PCR treatment Olimina3 medical study
PCR effect Olimina3
PCR scientific study

– 46 patients with CRP data. 70% had a decrease in CRP.
– Average decrease of 35% in CRP, statistically significant (p = 0.007).
– Reduction of CRP in all patient subgroups. The higher the CRP, the greater the reduction.
– Higher CRP level (cut-off level 2.5x), reduction of -> 47% in CRP, being significant on d30 (p = 0.03) and on d60 (p = 0.04).

Conclusions of the clinical study

olimina3
olimina3
olimina3
olimina3

Preclinical study

Preclinical in vitro* studies conducted by PHYTOGEN MEDICAL FOOS and its partners to determine the efficacy of HYTOLIVE®, have shown impressive results. All of these are consistent with the evidence from animal and human trials.

It has been shown that the polyphenols in extra virgin olive oil, contained in HYTOLIVE®, can help the body’s response to diseases caused by inflammatory processes*.

Preclinical research conducted with our ingredients has shown that HYTOLIVE® it inhibits the production of ROS (reactive oxygen species) by smooth muscle arterial cells, inhibits LDL oxidation and induces apoptosis 5 times more than the control vehicle in 3 of the 8 cell lines tested.

Journal of Clinical Oncology

Journal of Clinical Oncology

Breast cancer patients with higher levels of inflammatory proteins in the blood (CRP) were 2-3 times more likely to die than those with lower levels (n = 734).5

Cleveland Clinic

Cleveland Clinic

According to the Cleveland Clinic, the Harvard Women’s Health Study showed that high CRP levels were more predictive of coronary heart disease and stroke in women who had high cholesterol levels.6

Women's Hospital and Brighan

Women’s Hospital and Brighan

The Brigham and Women’s Hospital study concludes: Reducing inflammation without reducing cholesterol reduces the risk of cardiovascular events. published in New England Journal of Medicine, August 2017.8

Breast Cancer Research

Breast Cancer Research

Elevated CRP levels are associated with reduced overall and disease-free survival and increased risk of death (n = 2,910).9

Want to know more? Contact us!